The study objective was to show that fentanyl given five minutes prior to induction improved insertion conditions for the Classic Laryngeal Mask Airway. Previous work had shown fentanyl at 90 seconds to be unpredictable. A probit analysis design was used in which success/failure rates of different doses of fentanyl were measured and dose-response curves drawn from which the ED 50 and ED 95 with 95% confidence intervals were determined.
To provide reliable insertion conditions for the Classic Laryngeal Mask Airway (cLMA; Laryngeal Mask Company Ltd, Nicosia, Cyprus) a number of induction agents and adjuncts have been investigated [1] [2] [3] [4] [5] . Propofol 2.5 to 3.5 mg.kg -1 appears to be the most appropriate induction agent 1, 5 but the choice of adjunct is less clear. In Hong Kong, propofol co-administered with an opioid, usually fentanyl, is preferred. The most appropriate dose of fentanyl is undetermined, as too little results in difficult insertion conditions and too much in prolonged apnoea 6, 7 .
In a recent publication from our department, propofol (2.5 mg.kg -1 ) co-administered with either the opioid fentanyl (1 µg.kg -1 ) or alfentanil (10 µg.kg -1 ) were compared 8 . It was found that the shorter-acting opioid alfentanil provided better cLMA insertion conditions. However, only single and non-equipotent doses were compared. Therefore, we conducted a dose-response study using probit analysis to determine an optimum dosage of alfentanil to be used with 2.5 mg.kg -1 of propofol and recommended a 10 µg.kg -1 dose 6 . Probit analysis involves plotting the success/failure rates (dichotomous outcomes) of different dosages of a drug against dose on a logarithmic scale. Success rates are determined for groups of patients receiving the same dose. Several different doses are studied. From the resulting sigma shaped dose-response curve, effective doses for a 50% success rate (ED 50 ) and 95% success rate (ED 95 ) can be extrapolated 9 . However, alfentanil is less popular for cLMA insertion and far more expensive than fentanyl in Hong Kong, where a 1 mg ampoule of alfentanil is at least 25 times the cost of a 100 µg ampoule of fentanyl. Therefore, we repeated our dose-response cLMA insertion study with the more commonly used opioid fentanyl. We found that a standard 1 µg.kg -1 dose of fentanyl, co-administered with propofol 2.5 mg.kg -1 , provided optimal conditions in only 65% of cases and to achieve a 95% no response rate an excessively large dose of fentanyl in the range of 5 to 20 µg.kg -1 was needed 7 . However, this study could be criticised as only 90 seconds were allowed for the onset of the fentanyl analgesic effect and this may have been insufficient time. Ko and colleagues have suggested that three to five minutes be allowed for intravenous fentanyl to reach its peak effect when intubating the trachea 10 . Therefore, we repeated our fentanyl study but allowed more time, five minutes compared to 90 seconds, for the onset of the fentanyl effect before inserting the cLMA. Our objective was to determine an ideal dose for pre-induction fentanyl when coadministered with propofol 2.5 mg.kg -1 that would provide optimal insertion conditions in 95% of cases.
MATERIALS AND METHODS
The study was approved (Clinical Trials Registry number CRE-2007.020.T) by the Joint Chinese University of Hong Kong and New Territories East Cluster Clinical Research Ethics Committee (Shatin, New Territories, Hong Kong) and written informed consent was obtained.
Adult patients aged between 18 to 65 years and scheduled to undergo surgeries in which general anaesthesia with spontaneous breathing using a cLMA was deemed most appropriate were recruited. The exclusion criteria were high risk of aspiration, anticipated difficult airway (i.e. a Mallampati score 11 of 3 or 4, limited mouth-opening or intraoral pathology), body weight above 100 kg, use of sedative drugs or premedication and patient refusal.
Patients received one of six doses of fentanyl (0.25, 0.5, 1.0, 1.5, 2.0 or 3.0 µg.kg -1 ). The study was designed so that there were six groups of 16 patients, with an equal number of male (n=8) and female (n=8) patients in each group. Sequentially numbered data collection forms were used which gave each patient an identification number and this number was used to allocate the patient to a fentanyl group and dose. Separate forms for male and female patients were used. A second person not involved in assessing cLMA insertion looked up the dose of fentanyl using the identification number on a randomised dose chart and prepared the study drug. The corresponding dose had been randomly assigned by computer prior to commencement of the study. The investigator assessing the cLMA insertion was blinded to the assignment order. An assigned volume of fentanyl was drawn up into a syringe and diluted with normal saline to 10 ml, which was administered on a 0.1 ml per kg of body weight basis. For example, for the 1.0 µg.kg -1 group, 2 ml (100 µg) of fentanyl was added to 8 ml of saline to make 10 ml of solution, with a concentration of 10 µg.ml -1 . Therefore, if the patient weighed 70 kg, 7 ml of solution was given and the patient received 70 µg of fentanyl or 1.0 µg.kg -1 . Doses of 25, 50, 150, 200 and 300 µg of fentanyl were drawn up for the other five groups respectively.
No premedication was given. Each patient was pre-oxygenated for three minutes. The study drug fentanyl was injected and a timer started. After 3.5 minutes, anaesthesia was induced by injecting propofol (2.5 mg.kg -1 ) over 10 seconds. The patient remained unventilated throughout the induction period. A size 3 (in women) or a size 4 (in men) cLMA was then inserted 300 seconds after the injection of fentanyl and 90 seconds after the injection of the propofol. The technique recommended by Brain was used 12 . The cLMA was prepared with the cuff fully deflated and well lubricated. With the neck extended and jaw opened, the cLMA was inserted in the mid-line and advanced fully into the pharynx, following which the cuff was inflated with 15 to 20 ml of air until the cLMA tube was seen to rise slightly out of the patient's mouth. The tube was then secured to the patient's face.
Following insertion, the position of the cLMA was checked for airway patency by either observing the patient's respiratory movement and the capnogram when breathing spontaneously, or in apnoeic patients observing for chest expansion and the capnogram during manual ventilation. When the cLMA was found to be obstructed due to faulty placement or prolonged laryngospasm, it was removed and another dose of propofol (1 mg.kg -1 ) given, followed by another attempt at cLMA insertion made 60 seconds later. After three failed attempts at cLMA insertion and lung ventilation, the patient's airway was secured by tracheal intubation.
If the patient remained apnoeic for more than 30 seconds after cLMA insertion, the lungs were manually ventilated via the cLMA to maintain oxygen saturations above 95% and end-tidal carbon dioxide tensions between 5.3 and 6.6 kPa, until spontaneous ventilation resumed. Once the cLMA had been successfully inserted, anaesthesia was maintained with isoflurane and nitrous oxide in oxygen and no further data were collected.
DATA COLLECTION
Patient details, insertion conditions (described below) and duration of apnoea (cLMA insertion to first spontaneous breath) were recorded on a data collection form. The patient's blood pressure and heart rate were recorded before administrating the study dose of fentanyl, one minute after induction with propofol and one minute after cLMA insertion. In patients where multiple attempts at cLMA insertion were made and additional propofol was given, the duration of apnoea was excluded from the analysis.
A three-point, six-category scale that had been used in previous studies 3,6-8 was used to grade insertion conditions:
Resistance to mouth-opening grading: no, • significant or undue force required. Resistance to insertion grading: no, significant or • undue force required. Swallowing grading: nil, slight or gross.
•
Coughing and gagging grading: nil, slight or gross.
Head or body movement grading: nil, slight or • gross. Laryngospasm grading: nil, partial or total. • Laryngospasm was defined as a prolonged partial or complete obstruction with an apparently correctly placed cLMA.
In previous cLMA studies we had developed a optimum, or ideal, insertion conditions score based on swallowing, coughing and gagging, head or body movement and laryngospasm 6, 7 . Resistance to mouthopening and insertion were excluded because these assessments were considered to be too dependent on anatomical features. For the purpose of probit analysis, the assessment of optimum insertion conditions was converted to a dichotomous success/ failure score, where success meant that all four assessments were graded as 'nil', or no patient response was witnessed.
STUDy SIZE AND DESIgN
In a Cochran-Armitage test for trend in proportion, a sample size of six groups of 15 patients will achieve a 90% power to detect a linear trend using a two-sided Z test with continuity correction and a significance level of 0.05, assuming the success rates of 0.67, 0.75, 0.93, 0.98, 1.00 and 1.00 for 0.25, 0.5, 1.0, 1.5, 2 and 3 µg.kg -1 (PASS version 8, NCSS Inc., Kaysville, UT, USA). In order to achieve more narrow confidence intervals (CI) with equal numbers of males and female patients being recruited, we decided to increase each group to 16 patients. An additional fentanyl dose of 3.0 µg.kg -1 was added to the upper range to improve this part of the probit plot. We also replaced the placebo, or zero, dose with 0.25 µg.kg -1 to avoid uncertainty about its positioning on a log dose axis of the probit plot. In our previous studies we substituted a value of 0.2 µg.kg -1 for the placebo data point, because zero does not exist on a log scale.
STATISTICAL ANALySIS
Demographic data were compared using analysis of variance and chi-square test. Insertion conditions and apnoea were compared, with respect to increasing dosage, using the chi-square for trends 'linear association' test. Repeated-measures analysis of variance was used to determine the mean arterial pressure (MAP) and the heart rate over time (baseline, one minute after induction and one minute after cLMA insertion) with an interaction between dose and time included in the model. Statistical analysis was performed using SPSS (SPSS version 15.0, SPSS Inc., Chicago, IL, USA). The level of significance was set at P <0.05.
Probit analysis was used to estimate the ED 50 and ED 95 (95% CI) of all six cLMA insertion assessments and optimum conditions. The doseresponse analysis of each insertion condition and optimum conditions (four categories) were based on dichotomous outcomes (success [nil] or failure [slight or gross]).
The dose response curves for optimum insertion conditions for the present and our other two previous studies 6,7 were compared for parallelism by comparing the straight lines of best fit to the sigma shaped dose-response curves using the t-test method outlined by Tallarida 13 , incorporated into PharmTools Pro software, (McCary group, Elkins Park, PA, USA). If parallelism 13 was shown, then the relative potency could be determined by measuring the standard effect doses for the two drugs and calculating the ratio. Similar analysis was also performed to compare the dose response curves from our male and female cohorts.
RESULTS
We recruited 48 male and 48 female patients, aged 18 to 63 years. The six dosage groups were similar with respect to age, weight and ASA status ( Table 1 ). There was no difference in the incidence of incorrect positioning of the cLMA between the groups (P=0.83) and no difference in the proportion of patients requiring more than one attempt to secure the cLMA between the different fentanyl dose groups (P=0.77). There was no difference in the incidence of patients requiring additional propofol between the groups (P=0.61).
Insertion conditions
The incidence of resistance to mouth opening (chisquared for trends: P=0.01), swallowing (P=0.001), gagging and coughing (P=0.02) and movement (P <0.001) all decreased with increasing fentanyl dosage ( Figure 1 ). The incidence of resistance to cLMA insertion was too evenly distributed and the incidence of laryngospasm was too low for trend analysis to be performed. There was a notable increase in the incidence of a response to insertion with the 1.5 µg.kg -1 dose (Figure 1 ).
Increasing fentanyl dose was associated with greater duration of apnoea following induction and a higher incidence of prolonged apnoea (>five minutes: chi-squared for trends: P<0.001; Table 1 ).
Haemodynamic changes
Baseline MAP and heart rate were comparable in all six dosage groups ( Table 2 ). MAP decreased after injection of fentanyl and propofol in all six groups (P <0.01), from a mean of 100 mmHg to 79 to 90 mmHg. The decreases in MAP ranged from 10 to 19%. MAP was further decreased by 3 to 9% after cLMA insertion in the higher 1.0 to 3.0 µg.kg -1 fentanyl groups (P <0.04; Table 2 ).
Heart rate decreased in the 1.5 µg.kg -1 group after induction and in the 3.0 µg.kg -1 group after cLMA insertion (P <0.05). There were no significant changes in heart rate in the other four groups ( Table 2) .
Dose response curves
For resistance to insertion and laryngospasm the ED 50 and ED 95 could not be predicted because the CIs of the dose-response curves were very wide and could not be plotted with any certainty (Table 3) . For the other assessments of ED 50 and ED 95 the CIs were still wide but could be predicted (Table 3) . A fentanyl dose of 0.5 µg.kg -1 at which insertion conditions would be optimal in over 50% of cases was estimated ( Table 3) .
The commonly used 1 to 2 µg.kg -1 dosage range provided optimal insertion conditions in 70 to 80% of cases ( Figure 2) . A predicted fentanyl dose of 7.5 µg.kg -1 would ensure optimal cLMA insertion conditions in 95% of cases (Table 3, Figure 2 ).
Data from male and female patient cohorts were compared. The dose-response curves for optimal insertion conditions were plotted and the slopes were tested for parallelism 13 . There was no difference between the slopes (P=0.62). Therefore the potency of fentanyl in male and female patients was similar (Figure 3) . The ED 50 for this analysis was close to 0.5 µg.kg -1 and the ED 95 ranged from 5 to 11 µg.kg -1 (Table 3) .
Comparisons with previous data
Dose response data from our previous studies are summarised in the Appendix. The dose-response curve for optimal insertion conditions was plotted against similar data from our two previous cLMA probit studies ( Figure 2 ) 6,7 and the slopes were tested for parallelism 13 . The alfentanil and fentanyl (both given 90 seconds before cLMA insertion) curves had slopes that were significantly different (P=0.03), thus no relative potency estimates could be made over the range of their measured effects. However, the slopes of the alfentanil (90 seconds) and the new fentanyl (300 seconds) curve were not significantly different (P=0. 19) , and thus fentanyl (300 seconds), as given in this study, was shown to be 6.88 (95% CI 2.25 to 20.58) times more potent than alfentanil (90 seconds). There was also no difference between the slopes of the fentanyl (90 seconds) and fentanyl (300 seconds) curves (P=0.61) and the potencies were similar. The ED 50 and ED 95 of optimal conditions from our two previous probit studies are compared to our current data in Table 4 6, 7 . There was a decrease in the predicted fentanyl ED 95 from 21.6 to 7.4 µg.kg -1 when a wait of 300 seconds was used.
DISCUSSION
The overall effect of increasing the dose of coadministered fentanyl was to improve cLMA insertion conditions (Figure 1 ). However, a high proportion of cases still responded to cLMA insertion when using doses of fentanyl of 1.5 µg.kg -1 and to a lesser extent when using other higher doses (Figure 1 ). Reliable dose-response data for fentanyl could be plotted for most study outcomes. However, for the categories of resistance to insertion and laryngospasm the 95% CIs were very wide and dose- Figure 2 : Dose-response plot comparing the optimum conditions with opioid dose for the fentanyl in the present study (dotted line) and data from our two previous laryngeal mask studies 6, 7 . Probit curves are plotted using five or six data points. Each data point is based on data from 15/16 patients, males or females, for each selected fentanyl dose. Log scale used for x-axis. Fine dotted lines show ED 50 and ED 95 for optimum conditions for the fentanyl (300 seconds) plot. ED 50 and ED 95 with 95% confidence intervals (CI) derived from the dose-response curves for the six categories of Classic Laryngeal Mask Airway insertion assessment and optimal insertion conditions, which was based on swallowing, gagging, movement and laryngospasm response. gender comparison for optimal insertion conditions is also provided. * Upper limit of CI is difficult to predict with any certainty. Dose-response analysis could not be performed for two of the assessments. Predicted optimum dose was estimated from the mean effective doses for optimal insertion conditions. response data could not be predicted. The estimated ED 95 for fentanyl of 7.5 µg.kg -1 was higher than doses used clinically, but not as high as previously reported with fentanyl at 90 seconds 7 , which was 22 µg.kg -1 .
The commonly used 1 to 2 µg.kg -1 dose was predicted to provide optimal insertion conditions in 70 to 80% of cases ( Figure 2 ). This percentage was not dissimilar to that from fentanyl at 90 seconds 7 where optimum conditions were provided in 60 to 70% of cases. When our new data were compared to fentanyl at 90 seconds 7 , we found similar potencies and a slight improvement in the quality of the probit analysis ( Figure 2 ), suggesting that waiting an extra three to four minutes for the fentanyl to take full effect does marginally improve insertion conditions. When our latest fentanyl data were compared to alfentanil 6 , we were able to show a relative potency of seven times for fentanyl compared to alfentanil. This analysis had not been possible in the previous study, because of lack of consistency of the data 7 .
Visual inspection of the combined dose-response plots containing historical and present study data for both fentanyl and alfentanil ( Figure 2) showed that the probability of success (vertical y-axis) for fentanyl at 90 seconds ranged from 0.3 to 0.7, whereas for fentanyl at five minutes probability ranged from 0.25 to 0.95, and for alfentanil it ranged from 0.2 to 1.0. These differences in the spread of data are significant and help to explain the variation in reliability of the probit analysis from our different studies. In particular, the poor sigma curve fitting with fentanyl at 90 seconds can be attributed in part to the nature of the data collected and the limited range of y-axis data points (i.e. less than half the sigma plot range). However, fentanyl at five minutes had almost twice the range (i.e. 0.4 compared to 0.7), and this helps to explain the better predictability of the newer data. In the second fentanyl study we introduced a sixth dosage of 3 µg.kg -1 to improve the data range, which returned an upper value of 0.95 compared to 0.7 for the previous fentanyl study. However, the 2 µg.kg -1 data point in the second study was also 0.95 compared to 0.7 for the first study, so one cannot totally attribute the observed improvement in predictability of dosage when using a longer time interval to improved study design. The alfentanil data had an even larger data range of 0.2 to 1.0 and thus was even more predictable. However, the 1.5 µg.kg -1 dosage point of the present fentanyl study appeared to be a significant outlier with a value of 0.4, rather than 0.8 to fit in with the rest of the data, and this distracted from the overall quality of our results. The reason for this outlier was unclear, but may reflect study design and a need to use much larger patient groups in future, 15 to 16 patients per group being insufficient. Another important finding was the difference in relative ED 50 and ED 95 values between fentanyl and alfentanil. For fentanyl in the present study it increased from 0.5 to 7.5 µg.kg -1 , a 15-fold increase. In comparison, for alfentanil it increased from 5 to 18 µg.kg -1 , a four-fold increase 6 . In other words, the therapeutic range of alfentanil was much narrower and this allowed a clinically acceptable dose of 10 µg.kg -1 to be predicted that would provide almost perfect insertion conditions. A similar dose for fentanyl could not be determined.
An ideal time interval to wait between giving the intravenous fentanyl bolus and inserting the cLMA was not investigated. We chose five minutes because it was a straightforward time interval and previously Ko et al had suggested three to five minutes as optimal for laryngoscopy when using fentanyl 10 . Scholz et al quote a time interval of 4.5 minutes to peak fentanyl effect 15 , and similar time intervals are generated for fentanyl by pharmacokinetic models. Furthermore, when given intravenously to treat cancer pain fentanyl achieved its peak effect around five minutes after administration 16 . Therefore, it seems reasonable to conclude that waiting more that five minutes would not have further improved the success rate of cLMA insertion.
In our current cLMA study, we were able to improve our ability to predict outcomes, compared to our previous study 7 , by increasing the time between administering fentanyl and inserting the cLMA to five minutes and adjusting the data points to include 0.25 µg.kg -1 and 3.0 µg.kg -1 . We also eliminated gender imbalance between the groups, though this was later shown not to effect outcome (Figure 3 ). However, increasing the time between administration and insertion from 90 seconds to five minutes did not greatly improve insertion conditions, as complete suppression of reflexes (optimal insertion conditions) only increased from 65 to 70% for a 1.0 µg.kg -1 dose (Figure 2 ). As mentioned earlier, this may have been in part due to improvements in the study protocol in respect to dosages. Thus, allowing time for the fentanyl to take effect before inducing with propofol does not seem to have a major impact on cLMA insertion conditions, as suggested in our previous study 7 , but the most reliable method of guaranteeing ideal cLMA conditions is to use alfentanil instead of fentanyl.
Our data also provides useful information of the relative potencies of fentanyl and alfentanil during cLMA insertion. Stanski had previous reported that alfentanil was five to six times less potent than fentanyl, which is in keeping with data from our study of seven times lower potentcy 14 , although the 95% confidence limits for this value ranged from 2 to 20.
A number of recently published studies investigating fentanyl co-administered with propofol for cLMA insertion have also suggested that fentanyl dosage is difficult to predict, and we reviewed this in our previous cLMA publications 6, 7 . The degree of apnoea was slightly reduced in our present study compared to our previous study where fentanyl was given earlier 7 . However, we still found that doses of fentanyl in the latest study of 1 to 2 µg.kg -1 were associated with durations of apnoea following insertion of one to three minutes (Table 1) .
A number of alternative drug strategies also need to be considered. Midazolam is commonly used as a premedication, either given orally one hour before or intravenously immediately before induction of anaesthesia. We did not give our patients midazolam in this study, but its influence on cLMA insertion has been previously shown 17, 18 . Considering midazolam is commonly used in routine anaesthetic practice it would be certainly worthwhile studying the influence of this drug on cLMA insertion conditions during propofol-fentanyl induction. Furthermore, there has been a recent increase in interest in the use of propofol-remifentanil infusions and total intravenous anaesthesia for facilitating cLMA insertion 19, 20 . For short procedures the intense respiratory depressant effects of remifentanil can be overcome by the use of newer modes of ventilatory support. Whereas previously we had considered remifentanil unsuitable for short surgical procedures with a cLMA, practices are changing 6, 7 .
In conclusion, by increasing the wait time for co-administered fentanyl from 90 seconds to five minutes we were only able to marginally improve cLMA insertion conditions, and ideal conditions could not be achieved in every induction (ED 95 ), except with inappropriately high doses of fentanyl. A fentanyl dose of 1 to 2 µg.kg -1 given five minutes before cLMA insertion only provided ideal conditions in 70 to 80% of cases. Alfentanil 10 µg.kg -1 given 90 seconds before cLMA insertion, as shown by our previous study 6 , was a better choice, but at a significantly increased cost. The addition of a second adjunct, such as midazolam, may improve the success rate of fentanyl and thus merits further investigation. Newer techniques using remifentanil and total intravenous anaesthesia should also be considered.
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APPENDIX
Table showing historical probit data from previous alfentanil and fentanyl at 90-seconds studies 6, 7 . Predicted ED 50 and ED 95 doses for ideal cLMA insertion provided. N.B. For raw probability of success data at different doses, see Figure 2 . The opioid dose is given in the study protocol and success/failure rates are easily derived by knowing the group size (i.e. 15 or 16 patients) and extrapolating the probability of success from the sigma plot.
